“Ugh, I’m so busy these days I can barely think straight. It’s so crazy.” No doubt some friend or coworker (maybe even yourself) has moaned about how stressed and overworked they are. Sometimes its fully justified, but in many cases folks see it as “stress bragging,” or “busy bragging,” signaling how important and needed the person is. In those cases, stress bragging could do you more harm than good, new research shows. “This is a behavior we’ve all seen, and we all might be guilty of at some point,” said study author Jessica Rodell, a professor of management at the University of Georgia Athens’ Terry College of Business.  “When I was wondering about why people do this, I thought maybe we are talking about our stress because we want to prove we’re good enough,” she said in a university news release. “We found out that often backfires.” Instead of instilling respect and sympathy in co-workers, stress braggers often are looked upon as unlikable and less competent, the study found. The data was based on a survey of 360 adults who were told to imagine that a colleague had just returned from a business conference. These imaginary colleagues uttered a variety of statements. The stress-bragging worker said “Just one more thing on my full plate. And I was already stressed to the max … you have…  read on >  read on >

Does advising your teen sometimes feel like talking to the proverbial brick wall? Don’t fret: New research shows that even when your preteen or teen gives your advice a flat “no way,” your counsel is probably having an impact. It may simply be tucked away by your child, ready for use another day. “The kids are at an age where they’re maturing and wanting to make their own decisions,” explained study lead author and University of Illinois Urbana-Champaign researcher Kelly Tu. “Their immediate response may be resistance or reluctance, but the advice about how to reframe the problem, consider other explanations or think about what they are learning from the experience is sticking with them,” Tu said in a university news release. “They may need time to process and evaluate it. Maybe they didn’t find it useful in that specific situation they were discussing. But perhaps they came across new experiences in middle school and now they have some strategies to pull from their toolbox because mom gave them different ways to think about academic challenges.” Tu is associate professor of human development and family studies at the university. Her team published the study in the May-June issue of the Journal of Applied Developmental Psychology. The study focused on 100 mother-child pairs where the child was in the fifth grade. Tu said her team focused…  read on >  read on >

Ozempic provides a wide variety of health benefits for people with kidney disease and type 2 diabetes, a major clinical trial has found. The drug significantly reduces the risk of severe kidney events, heart problems and death from any cause in patients who have both conditions, researchers found. “These benefits signify a profound clinical impact saving kidneys, hearts and lives for patients with type 2 diabetes and chronic kidney disease,” said researcher Vlado Perkovic, provost of the University of New South Wales in Sydney, Australia. “Additionally, the reassuring safety findings further support the strong potential value of [Ozempic] in this population.” Chronic kidney disease affects more than 800 million people worldwide, and is particularly common among people with type 2 diabetes, researchers said in background notes. Ozempic was originally developed as a treatment for diabetes, as it helps control the release of insulin and keeps blood sugar levels lower. Its potential benefits for weight loss were later tested and approved. However, its potential to help people with kidney disease had not been fully examined, researchers said. For the study, investigators recruited more than 3,500 patients who had both kidney disease and type 2 diabetes. Patients were randomly chosen to receive weekly Ozempic (semaglutide) or a placebo. Patients taking Ozempic had a 24% lower risk of kidney problems, heart disease and death related to either the…  read on >  read on >

Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from first use more than a third have stopped, new research shows. Reasons for quitting Wegovy, Ozempic or similar drugs may include cost or gastrointestinal side effects, said a team led by Urvashi Patel, of the Evernorth Research Institute in St. Louis. The drugs’ price tag could be a big factor: Wegovy (semaglutide) costs about $1,300 per month, for example. “Each 1–percentage point increase in out-of-pocket cost per a 30-day supply of GLP-1 agonist was associated with increased odds of discontinuation,” Patel’s group noted. They published the findings May 23 in the journal JAMA Network Open. The St. Louis team looked at information from a major U.S. drug database on the use of GLP-1 meds by adults from early 2021 through to the end of 2023. Tirzepatide (Zepbound) was excluded from the list of GLP-1 meds because it was only approved by the U.S. Food and Drug Administration at the end of 2023. The database of nearly 196,000 patients found that by three months after starting a GLP-1 drug, just over 26% of users had already discontinued use; by six months that had risen to just under 31%, and by a year out 36.5% had stopped taking their GLP-1…  read on >  read on >

About 1 in 9 American children have ever received an ADHD diagnosis, slightly more than the number of kids currently being treated for the disorder, a new study shows. About 7.1 million kids (11.4%) have ever been diagnosed with ADHD, according to findings published May 23 in the Journal of Clinical Child & Adolescent Psychology. Incidence appears to be rising: Approximately 1 million more children ages 3 to 17 had received an ADHD diagnosis in 2022 than in 2016, researchers found. About 6.5 million children (10.5%) currently live with ADHD, or about 93% of those who’ve ever been diagnosed, researchers found. Among kids currently dealing with ADHD, about 58% have moderate or severe ADHD and 78% have at least one other disorder, results show.   Nearly 54% of current ADHD patients have been prescribed medication for the disorder, and 44% have received behavioral treatment in the past year, researchers found. However, nearly one in three kids (30%) haven’t received any ADHD-specific treatment, results show. ADHD is more common in the United States than in other countries, the researchers found. For the study, researchers analyzed more than 45,000 interviews conducted as part of the 2022 National Survey of Children’s Health. “Public awareness of ADHD has changed over time,” the researchers said. “With increased awareness of symptoms related to attention regulation, ADHD has been increasingly recognized in girls,…  read on >  read on >

The number of American teens and young adults who’ve been prescribed one of the new GLP-1 weight-loss drugs soared nearly seven-fold between 2020 and 2023, a new report finds. That’s compared to an overall decline of about 3% in young Americans’ use of other types of prescription meds. But how safe are drugs like Ozempic, Wegovy, Mounjaro and Zepbound for young users? That remains unclear, said a team led by Dr. Joyce Lee, a professor of pediatrics at the University of Michigan Medical School in Ann Arbor. “Evaluation of the long-term safety, efficacy and cost- effectiveness of GLP-1RAs in adolescents and young adults is needed,” her team wrote. The findings were published May 22 in the Journal of the American Medical Association. The new study used a major U.S. prescription drug database to calculate the medication use of adolescents (ages 12 to 17) and young adults (ages 18 to 25) for the years 2020 through 2023. Besides the four drugs mentioned above, the GLP-1 meds that were tracked included dulaglutide (Trulicity), exenatide (Byetta) and liraglutide (Saxenda). Lee’s team found that over the three years of the study, GLP-1 prescriptions among people ages 12 to 25 jumped by more than 594% (equivalent to a nearly sevenfold rise). In sheer numbers, that means that while 8,722 Americans in this age group took a GLP-1 in 2020, 60,567…  read on >  read on >

Folks regularly taking fish oil supplements might not be helping their health as much as they might think, a new study suggests. Regular use of fish oil supplements could increase the risk of first-time heart disease and stroke among those with good heart health, new research suggests. However, the long-term study also found that fish oil can help those whose hearts are already in trouble, potentially slowing the progression of heart problems and lowering the risk of death. Healthy people taking fish oil supplements had a 13% increased risk of developing atrial fibrillation, a heart rhythm problem that increases the risk of heart attack and stroke, researchers found. They also had a 5% increased risk of stroke, results show. “Our findings suggest caution in the use of fish oil supplements for primary prevention because of the uncertain cardiovascular benefits and adverse effects,” wrote the research team led by Dr. Hualiang Lin, an epidemiologist with Sun Yat-Sen University in Guangzhou, China. But in those with existing heart disease, regular use of fish oil lowered risk of a heart attack due to atrial fibrillation by 15%, and the risk of heart failure leading to death by 9%. “Regular use of fish oil supplements might have different roles in the progression of cardiovascular disease,” based on whether someone already has heart problems, the researchers suggested. “Overall, I would…  read on >  read on >

Doctors have long known that excessive marijuana use can trigger psychosis, especially in the young. But new research suggests the link is stronger that ever imagined before. Teens who use cannabis face 11 times the odds for a psychotic episode compared to teens who abstain from the drug, new Canadian research contends. The teen years may be an especially vulnerable time in this regard, the researchers noted. “We found a very strong association between cannabis use and risk of psychotic disorder in adolescence. Surprisingly, we didn’t find evidence of association in young adulthood,” said lead author André McDonald, who led the study as part of his PhD work at the University of Toronto. The findings were published May 22 in the journal Psychological Medicine. McDonald finished the research while at the Institute for Clinical Evaluative Sciences (ICES). Psychotic episodes involve a dangerous psychiatric state in which people lose their connection with reality. These episodes can get so out of control that people may need hospitalization. It’s long been known that marijuana use can help trigger psychosis, and the potency of cannabis is much stronger now than in decades past, the Toronto investigators noted. They estimate that the average THC potency of cannabis in Canada rose from roughly 1% in 1980 to 20% in 2018.  So how is all that super-strong weed affecting the developing brains…  read on >  read on >

Improved inhalers are now available to help control asthma and treat sudden attacks, but a new study shows that hardly anyone’s using them. The new inhalers combine inflammation-fighting corticosteroids with a long-acting drug called formoterol that opens up the airways, researchers report. These combo inhalers are used twice a day to treat moderate to severe asthma, and they can also be used as a rescue inhaler during an asthma attack. Guidelines from both the National Asthma Education and Prevention Program and the Global Initiative for Asthma now recommend the use of what are called “SMART” inhalers. But fewer than 1 in 6 adults with moderate or severe asthma have been prescribed a SMART inhaler, and more than 2 of 5 lung and allergy specialists haven’t adopted the combo therapy, researchers found. “Our findings suggest current asthma management guidelines are not being routinely implemented or adopted by clinicians,” said senior study author Dr. Sandra Zaeh, a pulmonary and critical care medicine physician at Yale University School of Medicine. Previous guidelines have recommended the use of maintenance inhalers twice a day, in addition to a short-acting rescue inhaler containing a drug like albuterol that opens airways, researchers said. By 2021, U.S. guidelines had been updated to recommend Single combination corticosteroid and formoterol inhaler for both Maintenance And Relief Therapy (SMART). SMART inhalers available in the United States…  read on >  read on >

You’ve watched others shed pounds in a matter of weeks after taking one of the new blockbuster weight-loss drugs, so you decide to try one of the medications yourself, only to discover the needle on your bathroom scale barely budges. Why? New research presented Monday at the Digestive Disease Week conference in Washington, D.C., suggests genes might be at play. Some patients will lose 20% or more of their body weight, but one study found that roughly 1 in 7 people who used the GLP-1 agonist semaglutide for more than a year didn’t lose at least 5% of their starting weight. Now, research shows that a new test that assigns a genetic risk score to patients may be able to spot who is likely to be successful on injected weight-loss medications. The test, MyPhenome, was developed by researchers at the Mayo Clinic and licensed last year by a company they founded called Phenomix Sciences. It costs $350 and must be ordered by a health care provider, CNN reported. “Our data support that obesity has a strong genetic and biological basis that varies within patients living with obesity,” lead investigator Dr. Maria Daniela Hurtado Andrade said in a company news release. “Furthermore, our results underscore the potential of individualizing therapy to improve outcomes that will ultimately translate into improved health.” “We think that the test will be…  read on >  read on >